Compare SHC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHC | LEGN |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.9B |
| IPO Year | 2020 | 2020 |
| Metric | SHC | LEGN |
|---|---|---|
| Price | $15.35 | $18.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $20.67 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 2.6M | 1.2M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.75 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $1,163,617,000.00 | N/A |
| Revenue This Year | $7.51 | $42.19 |
| Revenue Next Year | $6.00 | $33.29 |
| P/E Ratio | $56.91 | ★ N/A |
| Revenue Growth | ★ 5.74 | N/A |
| 52 Week Low | $10.17 | $16.24 |
| 52 Week High | $19.85 | $45.30 |
| Indicator | SHC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 48.10 |
| Support Level | $15.19 | $17.46 |
| Resistance Level | $16.55 | $19.36 |
| Average True Range (ATR) | 0.43 | 0.71 |
| MACD | 0.30 | 0.07 |
| Stochastic Oscillator | 95.94 | 51.69 |
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe and other regions.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.